Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis.

Liu H, Stresser DM, Michmerhuizen MJ, Li X, Othman AA, Reed AD, Schrimpf MR, Sydor J, Lee AJ.

Drug Metab Dispos. 2018 Apr;46(4):429-439. doi: 10.1124/dmd.117.077511. Epub 2018 Jan 18. Erratum in: Drug Metab Dispos. 2018 Sep;46(9):1382.

PMID:
29348125
2.

Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.

Zhang JG, Wang D, Ho T, Clark RJ, Stresser DM.

Drug Metab Lett. 2017;11(2):119-127. doi: 10.2174/1872312811666171128141105.

PMID:
29189189
3.

In Vitro Drug Metabolism Using Liver Microsomes.

Knights KM, Stresser DM, Miners JO, Crespi CL.

Curr Protoc Pharmacol. 2016 Sep 16;74:7.8.1-7.8.24. doi: 10.1002/cpph.9.

PMID:
27636111
4.

Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole.

Stresser DM, Perloff ES, Mason AK, Blanchard AP, Dehal SS, Creegan TP, Singh R, Gangl ET.

Drug Metab Dispos. 2016 Aug;44(8):1424-30. doi: 10.1124/dmd.116.070193. Epub 2016 May 5.

PMID:
27149898
5.

Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes.

Zhang JG, Ho T, Callendrello AL, Clark RJ, Santone EA, Kinsman S, Xiao D, Fox LG, Einolf HJ, Stresser DM.

Drug Metab Dispos. 2014 Sep;42(9):1379-91. doi: 10.1124/dmd.114.058602. Epub 2014 Jun 12.

PMID:
24924386
6.

Exploring concepts of in vitro time-dependent CYP inhibition assays.

Stresser DM, Mao J, Kenny JR, Jones BC, Grime K.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):157-74. doi: 10.1517/17425255.2014.856882. Epub 2013 Nov 21. Review.

PMID:
24256452
7.

Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.

Henne KR, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK.

Drug Metab Dispos. 2012 Jul;40(7):1429-40. doi: 10.1124/dmd.112.045708. Epub 2012 Apr 19.

PMID:
22517972
8.
9.

Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells.

McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, Riley RJ.

Drug Metab Dispos. 2009 Jun;37(6):1259-68. doi: 10.1124/dmd.109.026526. Epub 2009 Mar 23.

PMID:
19307295
10.

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.

Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM.

Xenobiotica. 2009 Feb;39(2):99-112. doi: 10.1080/00498250802638155.

PMID:
19255936
11.

Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine.

Stresser DM, Mason AK, Perloff ES, Ho T, Crespi CL, Dandeneau AA, Morgan L, Dehal SS.

Drug Metab Dispos. 2009 Apr;37(4):695-8. doi: 10.1124/dmd.108.025726. Epub 2009 Jan 14.

PMID:
19144769
12.

David Kupfer: a career retrospective.

Stresser DM.

Drug Metab Rev. 2006;38(1-2):3-12.

PMID:
16684644
13.

Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.

Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J.

Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24.

PMID:
16501008
14.

Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL.

Drug Metab Dispos. 2004 Jan;32(1):105-12.

PMID:
14709627
15.

In vitro and pharmacophore insights into CYP3A enzymes.

Ekins S, Stresser DM, Williams JA.

Trends Pharmacol Sci. 2003 Apr;24(4):161-6. Review.

PMID:
12707001
16.

Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay.

Kragie L, Turner SD, Patten CJ, Crespi CL, Stresser DM.

Endocr Res. 2002 Aug;28(3):129-40.

PMID:
12489563
17.

Design and application of fluorometric assays for human cytochrome P450 inhibition.

Crespi CL, Miller VP, Stresser DM.

Methods Enzymol. 2002;357:276-84. No abstract available.

PMID:
12424917
18.

Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4.

Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL.

Drug Metab Dispos. 2002 Jul;30(7):845-52.

PMID:
12065444
19.

Concurrent flavin-containing monooxygenase down regulation and cytochrome P450 induction by dietary indoles in the rat: implication for drug-drug interactions.

Williams DE, Katchamar S, Larsen-Su SA, Stresser DM, Dehal SS, Kupfer D.

Adv Exp Med Biol. 2001;500:635-8. No abstract available.

PMID:
11765009
20.

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, Ackermann JM, Turner SD, Miller VP, Crespi CL.

Drug Metab Dispos. 2001 Sep;29(9):1196-200.

PMID:
11502727
21.

Fluorometric screening for metabolism-based drug--drug interactions.

Crespi CL, Stresser DM.

J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):325-31.

PMID:
11274899
22.

Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL.

Drug Metab Dispos. 2000 Dec;28(12):1440-8.

PMID:
11095581
23.

Fluorometric high-throughput screening for inhibitors of cytochrome P450.

Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL.

Ann N Y Acad Sci. 2000;919:26-32.

PMID:
11083094
24.

A high-throughput screen to identify inhibitors of aromatase (CYP19).

Stresser DM, Turner SD, McNamara J, Stocker P, Miller VP, Crespi CL, Patten CJ.

Anal Biochem. 2000 Sep 10;284(2):427-30. No abstract available.

PMID:
10964434
25.

Concurrent flavin-containing monooxygenase down-regulation and cytochrome P-450 induction by dietary indoles in rat: implications for drug-drug interaction.

Katchamart S, Stresser DM, Dehal SS, Kupfer D, Williams DE.

Drug Metab Dispos. 2000 Aug;28(8):930-6.

PMID:
10901703
26.

Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity.

Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM.

Life Sci. 1999;65(15):PL209-14.

PMID:
10574228
27.

Monospecific antipeptide antibody to cytochrome P-450 2B6.

Stresser DM, Kupfer D.

Drug Metab Dispos. 1999 Apr;27(4):517-25.

PMID:
10101147
29.
30.
32.
33.

Induction of hepatic CYP1A by indole-3-carbinol in protection against aflatoxin B1 hepatocarcinogenesis in rainbow trout.

Takahashi N, Stresser DM, Williams DE, Bailey GS.

Food Chem Toxicol. 1995 Oct;33(10):841-50.

PMID:
7590528
34.

Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats.

Stresser DM, Williams DE, Griffin DA, Bailey GS.

Drug Metab Dispos. 1995 Sep;23(9):965-75.

PMID:
8565787
35.

The anticarcinogen 3,3'-diindolylmethane is an inhibitor of cytochrome P-450.

Stresser DM, Bjeldanes LF, Bailey GS, Williams DE.

J Biochem Toxicol. 1995 Aug;10(4):191-201.

PMID:
8568833
36.

Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit.

Shehin-Johnson SE, Williams DE, Larsen-Su S, Stresser DM, Hines RN.

J Pharmacol Exp Ther. 1995 Mar;272(3):1293-9.

PMID:
7891346

Supplemental Content

Loading ...
Support Center